KTKEGV repeat motifs are key mediators of normal α-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 31, 2015, Pages 9596-9601

  Dettmer, Ulf ^a   Newman, Andrew J ^a   Von Saucken, Victoria E ^a   Bartels, Tim ^a   Selkoe, Dennis ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alpha synuclein; Multimer; Neurotoxicity; Parkinson's disease; Tetramer

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN; KTKEGV PROTEIN; MONOMER; PROTEIN; RED FLUORESCENT PROTEIN; TETRAMER; UNCLASSIFIED DRUG; CROSS LINKING REAGENT; MUTANT PROTEIN;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; GENE DELETION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MEDIATOR; MISSENSE MUTATION; MUTAGENESIS; NERVE CELL; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN MOTIF; AMINO ACID SEQUENCE; ANIMAL; CELL DEATH; CELL INCLUSION; CHEMISTRY; CONSERVED SEQUENCE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ALPHA-SYNUCLEIN; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL DEATH; CONSERVED SEQUENCE; CROSS-LINKING REAGENTS; HUMANS; INCLUSION BODIES; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; NEURONS; PROTEIN MULTIMERIZATION; RATS, SPRAGUE-DAWLEY; REPETITIVE SEQUENCES, AMINO ACID; SEQUENCE DELETION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84938629416     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1505953112     Document Type: Article

References (35)

1. Chandra S, et al. (2004) Double-knockout mice for alpha- and beta-synucleins: Effect on synaptic functions. Proc Natl Acad Sci USA 101(41):14966-14971.
2. Scott D, Roy S (2012) α-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci 32(30):10129-10135.
3. Wang L, et al. (2014) α-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol 24(19):2319-2326.
4. Spillantini MG, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645): 839-840.
5. Krüger R, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18(2):106-108.
6. Polymeropoulos MH, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047.
7. Zarranz JJ, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164-173.
8. Singleton AB, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302(5646):841.
9. Bartels T, Choi JG, Selkoe DJ (2011) α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362):107-110.
10. Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D (2013) In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and nonneural cells. J Biol Chem 288(9):6371-6385.
11. Newman AJ, Selkoe D, Dettmer U (2013) A new method for quantitative immunoblotting of endogenous α-synuclein. PLoS One 8(11):e81314.
12. Wang W, et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108(43):17797-17802.
13. Westphal CH, Chandra SS (2013) Monomeric synucleins generate membrane curvature. J Biol Chem 288(3):1829-1840.
14. Burré J, Sharma M, Südhof TC (2014) α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA 111(40):E4274-E4283.
15. Gurry T, et al. (2013) The dynamic structure of α-synuclein multimers. J Am Chem Soc 135(10):3865-3872.
16. Gould N, et al. (2014) Evidence of native α-synuclein conformers in the human brain. J Biol Chem 289(11):7929-7934.
17. Manning LR, et al. (2007) Human embryonic, fetal, and adult hemoglobins have different subunit interface strengths. Correlation with lifespan in the red cell. Protein Sci 16(8):1641-1658.
18. Gaglia G, Guan Y, Shah JV, Lahav G (2013) Activation and control of p53 tetramerization in individual living cells. Proc Natl Acad Sci USA 110(38):15497-15501.
19. Cole NB, et al. (2002) Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem 277(8):6344-6352.
20. Burré J, et al. (2013) Properties of native brain α-synuclein. Nature 498(7453):E4-E6; discussion E6-E7.
21. Fauvet B, et al. (2012) α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem 287(19):15345-15364.
22. Michell AW, et al. (2007) The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant 16(5):461-474.
23. Outeiro TF, et al. (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PloS One 3(4):e1867.
24. Wolfe MS, et al. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 398(6727):513-517.
25. Kara E, et al. (2013) α-Synuclein mutations cluster around a putative protein loop. Neurosci Lett 546:67-70.
26. Golebiewska U, Zurawsky C, Scarlata S (2014) Defining the oligomerization state of ã-synuclein in solution and in cells. Biochemistry 53(2):293-299.
27. Pranke IM, et al. (2011) α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. J Cell Biol 194(1): 89-103.
28. Chung CY, et al. (2013) Identification and rescue of α-synuclein toxicity in Parkinson patient-derived neurons. Science 342(6161):983-987.
29. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273(16): 9443-9449.
30. Burré J, Sharma M, Südhof TC (2015) Definition of a molecular pathway mediating α-synuclein neurotoxicity. J Neurosci 35(13):5221-5232.
31. Fonseca-Ornelas L, et al. (2014) Small molecule-mediated stabilization of vesicleassociated helical α-synuclein inhibits pathogenic misfolding and aggregation. Nat Commun 5:5857.
32. Galvagnion C, et al. (2015) Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. Nat Chem Biol 11(3):229-234.
33. Dettmer U, et al. (2010) Transmembrane protein 147 (TMEM147) is a novel component of the Nicalin-NOMO protein complex. J Biol Chem 285(34):26174-26181.
34. Kahle PJ, et al. (2000) Subcellular localization of wild-type and Parkinson's diseaseassociated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 20(17):6365-6373.
35. Baulac S, LaVoie MJ, Strahle J, Schlossmacher MG, Xia W (2004) Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Mol Cell Neurosci 27(3):236-246.